Cabio Biotech (Wuhan) Co., Ltd. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 273.24 million compared to CNY 249.91 million a year ago. Revenue was CNY 273.24 million compared to CNY 249.91 million a year ago.

Net income was CNY 77.87 million compared to CNY 100.95 million a year ago. Basic earnings per share from continuing operations was CNY 0.4643 compared to CNY 0.6 a year ago. Diluted earnings per share from continuing operations was CNY 0.4643 compared to CNY 0.6 a year ago.